Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Maxcyte (MXCT) EBIT (2020 - 2025)

Maxcyte (MXCT) has disclosed EBIT for 6 consecutive years, with $31.3 million as the latest value for Q4 2025.

  • Quarterly EBIT rose 5.34% to $31.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$9.4 million through Dec 2025, down 9.19% year-over-year, with the annual reading at -$9.4 million for FY2025, 9.19% down from the prior year.
  • EBIT for Q4 2025 was $31.3 million at Maxcyte, up from -$14.1 million in the prior quarter.
  • The five-year high for EBIT was $32.2 million in Q4 2023, with the low at -$14.2 million in Q2 2025.
  • Average EBIT over 5 years is -$2.9 million, with a median of -$8.2 million recorded in 2022.
  • Peak annual rise in EBIT hit 577.57% in 2023, while the deepest fall reached 216.85% in 2023.
  • Over 5 years, EBIT stood at $9.2 million in 2021, then tumbled by 173.17% to -$6.8 million in 2022, then soared by 577.57% to $32.2 million in 2023, then decreased by 7.84% to $29.7 million in 2024, then grew by 5.34% to $31.3 million in 2025.
  • According to Business Quant data, EBIT over the past three periods came in at $31.3 million, -$14.1 million, and -$14.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.